Advances recognized by science’s most lucrative awards include high-energy physics experiments and groundbreaking weight-loss ...
Novo Nordisk is licensing Lexicon Pharmaceuticals' experimental obesity drug in a deal worth up to $1 billion, the Danish ...
Novo Nordisk has licensed an oral obesity drug that works via an uncommon mechanism and may help patients maintain their ...
Novo Nordisk is taking aim at Eli Lilly with a new obesity drug deal. Meanwhile, a survey shows doctors’ perception of the ...
Rhythm Pharmaceuticals said on Monday that its experimental drug to treat a rare obesity disorder met the main goal in a late-stage trial.
The Trump administration rejected a proposed rule to allow Medicare to cover blockbuster obesity drugs for weight loss alone ...
This is a major source of cardiovascular morbidity and mortality. We have never been able to treat lipoprotein(a) until now.” ...
Whether or not you choose to cover weight loss drugs, offering holistic support can make a meaningful difference in employee ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback